In today's healthcare landscape, there is a pressing need for quantitative methodologies that include the patients' ...

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

Lynozyfic (linvoseltamab) has been given accelerated approval by the US regulator for adults with relapsed or refractory ...

The UK’s regulator, the MHRA, will be running five pilot dialogues as part of its first year exploring a real-world evidence ...

UK Prime Minister Sir Keir Starmer is due to reveal the long-awaited 10 Year Plan for the NHS later today, but revealed some ...

Returning as the industry’s definitive forum from early discovery to clinical development, the 8th Annual TPD & Induced ...

For AI to be transformative in the pharmaceutical industry, it must be designed with a security-first approach. This means ...

Finding a conversation about AI at a conference like BIO 2025 is easy. But making those conversations meaningful and asking ...

The transition from writing to programming regulatory submissions represents one of the most significant efficiency ...

The CGM is based on magnetohydrodynamic (MHD) technology, which non-invasively samples interstitial fluid, the body fluid ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

According to the government, the passport will eliminate multiple compliance assessments, reducing duplication across the ...